205.97
Iqvia Holdings Inc stock is traded at $205.97, with a volume of 886.74K.
It is down -0.52% in the last 24 hours and up +12.28% over the past month.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
See More
Previous Close:
$207.04
Open:
$205.44
24h Volume:
886.74K
Relative Volume:
0.54
Market Cap:
$34.38B
Revenue:
$16.63B
Net Income/Loss:
$1.39B
P/E Ratio:
25.53
EPS:
8.0674
Net Cash Flow:
$2.12B
1W Performance:
+6.57%
1M Performance:
+12.28%
6M Performance:
-14.37%
1Y Performance:
+25.41%
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, NTRA, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IQV
Iqvia Holdings Inc
|
205.97 | 32.25B | 16.63B | 1.39B | 2.12B | 8.0674 |
|
TMO
Thermo Fisher Scientific Inc
|
517.60 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
193.62 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
564.98 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
|
NTRA
Natera Inc
|
283.80 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
WAT
Waters Corp
|
378.89 | 36.82B | 3.77B | 449.25M | 240.68M | 7.8556 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Mar-06-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-03-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-29-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-09-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
IQVIA Holdings Inc (IQV) Stock Up 5.2% and Still Undervalued -- GF Score: 90/100 - GuruFocus
IQVIA Holdings highlights its data-driven healthcare platform. Investors focus on long-term growth p - AD HOC NEWS
Baird Adjusts Price Target on IQVIA Holdings Inc to $249 From $230, Maintains Outperform Rating - marketscreener.com
The IQVIA MedTech Acceleratordata-driven support for smaller device makers - AD HOC NEWS
IQVIQVIA Holdings Inc Latest SEC Filings - Finviz
Are Wall Street analysts predicting IQVIA Holdings stock will climb or sink? - MSN
IQVIA Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
IQVIA Holdings updates AI-powered analytics push, shares on NYSE radar - AD HOC NEWS
IQVIA Life Sciences Hub from IQVIA Holdingsunified data backbone for pharma teams - AD HOC NEWS
The Orchestrated Patient Recruitment from IQVIA Holdings Inc.data-driven outreach for tough trial - AD HOC NEWS
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MSN
IQVIA Holdings Inc Actuals & Estimates (NYSE:IQV) - TradingView
IQVIA Holdings EPS outlook lifted, shares anchored in S&P 500 healthcare tech - Ad-hoc-news.de
(IQV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Charles River upgraded, IQVIA downgraded as Morgan Stanley revisits CRO coverage - MSN
IQVIA Holdings consensus stays constructive, shares trade near record territory - Ad-hoc-news.de
IQV Forecast — Price Target — Prediction for 2027 - TradingView
QTS Forecast — Price Target — Prediction for 2027 - TradingView
IQVIA Holdings chart picture stays robust, shares above key 200-day mark - Ad-hoc-news.de
Is IQVIA (IQV) Balancing Slower Revenue Momentum With Its Latest Debt Refinancing Move? - Sahm
IQVIA Holdings Inc (IQV) Shares Surge 8.4% -- What GF Score of 8 - GuruFocus
IQVIA Holdings Jumps 7.4% Amid Sector-Wide Rally - AlphaStreet
Barclays Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $210 - Moomoo
IQVIA - Forbes
Pharmacovigilance Automation Market Size to Reach USD 5.25 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
OCE from IQVIA Holdings Inc.cloud CRM that speaks pharma’s language - Ad-hoc-news.de
Does Slower Growth at IQVIA Holdings (IQV) Challenge Its Core Data‑Driven Pharma Enablement Story? - Yahoo Finance
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
IQVIA Holdings trades in a tight range, technicals flag cautious signal for the shares - AD HOC NEWS
IQVIA Holdings Inc (IQV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IQVIA Holdings analyst views shift, shares trade below recent targets - Ad-hoc-news.de
IQVIA Holdings, Inc. (IQV): Investor Outlook On A 34% Potential Upside - DirectorsTalk Interviews
IQVIA Holdings Inc (IQV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IQVIA HoldingsAnalyst consensus and long-term drivers - AD HOC NEWS
Why IQVIA’s Orchestrated Customer Engagement quietly shapes pharma sales - AD HOC NEWS
IQVIA Holdings StockMorgan Stanley cuts rating and trims target - Ad-hoc-news.de
Morgan Stanley Maintains IQVIA Holdings(IQV.US) With Hold Rating, Raises Target Price to $225 - Moomoo
IQV News | IQVIA HOLDINGS INC (NYSE:IQV) - ChartMill
IQVIA Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
IQVIA Holdings Inc (IQV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IQVIA Holdings Inc (IQV) Valuation: PE, PB & Fair Value Analysis - TradingKey
IQVIA Holdings Inc (IQV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IQVIA Holdings Inc (IQV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IQVIA Holdings Inc (IQV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Saratoga Health & Biotechnology Fund's IQVIA Holdings Inc(IQV) Holding History - GuruFocus
IQVIA Holdings Inc (IQV) Institutional Confidence - TradingKey
IQVIA Holdings Inc (IQV) Stock Price, Trades & News - GuruFocus
Is IQVIA Holdings Inc (IQV) a Bargain After 4.7% Drop? GF Value Says Undervalued - GuruFocus
IQVIA Holdings Inc (IQV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IQVIA Holdings, Inc. Stock 12‑Month Price Target Cut to $223.28, Implies 25% Upside - TradingView
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iqvia Holdings Inc Stock (IQV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BOUSBIB ARI | See Remarks |
Dec 18 '25 |
Sale |
222.43 |
36,564 |
8,132,931 |
820,599 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):